

# Roberto Agresti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9431459/publications.pdf>

Version: 2024-02-01

74  
papers

3,211  
citations

186265

28  
h-index

149698

56  
g-index

77  
all docs

77  
docs citations

77  
times ranked

4474  
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4054-4059.	1.6	301
2	HER2 as a Prognostic Factor in Breast Cancer. <i>Oncology</i> , 2001, 61, 67-72.	1.9	216
3	Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCORE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2191-2205.	2.8	205
4	Association between [ <sup>18</sup> F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1429-1434.	6.4	161
5	Axillary Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-D-glucose-Positron Emission Tomography: Clinical Evaluation and Alternative Management. <i>Journal of the National Cancer Institute</i> , 2001, 93, 630-635.	6.3	153
6	Role of HER2 in wound-induced breast carcinoma proliferation. <i>Lancet</i> , The, 2003, 362, 527-533.	13.7	152
7	Conservation Surgery After Primary Chemotherapy in Large Carcinomas of the Breast. <i>Annals of Surgery</i> , 1995, 222, 612-618.	4.2	142
8	Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up. <i>Annals of Surgical Oncology</i> , 2011, 18, 125-133.	1.5	141
9	Breast Cancer Patients Treated Without Axillary Surgery. <i>Annals of Surgery</i> , 2000, 232, 1-7.	4.2	126
10	Quantitative and qualitative cosmetic evaluation after conservative treatment for breast cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 1395-1400.	0.7	125
11	Axillary Dissection Versus No Axillary Dissection in Older Patients With T1N0 Breast Cancer. <i>Annals of Surgery</i> , 2012, 256, 920-924.	4.2	114
12	HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. <i>Annals of Oncology</i> , 2001, 12, S15-S19.	1.2	112
13	Expression of protein tyrosine phosphatase alpha (RPTP $\alpha$ ) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. <i>Oncogene</i> , 2000, 19, 4979-4987.	5.9	77
14	Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98). <i>Cancer</i> , 2014, 120, 885-893.	4.1	68
15	FDG-PET for axillary lymph node staging in primary breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, S97-S102.	6.4	62
16	Identification of Breast Cancer-Restricted Antigens by Antibody Screening of SKBR3 cDNA Library Using a Preselected Patient's Serum. <i>Breast Cancer Research and Treatment</i> , 2002, 73, 245-256.	2.5	59
17	Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 442-450.	1.5	58
18	Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. <i>Annals of Oncology</i> , 2014, 25, 352-357.	1.2	53

#	ARTICLE	IF	CITATIONS
19	Immunological and pathobiological roles of fibulin-1 in breast cancer. <i>Oncogene</i> , 2004, 23, 2153-2160.	5.9	45
20	Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. <i>Cancers</i> , 2019, 11, 911.	3.7	40
21	Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1278-1289.	4.6	39
22	The influence of radiotherapy on cosmetic outcome after breast conservative surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 59-64.	0.8	37
23	Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-Year results of trial and out-trial patients. <i>European Journal of Surgical Oncology</i> , 2014, 40, 805-812.	1.0	37
24	PDGFR $\beta$ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. <i>Molecular Oncology</i> , 2014, 8, 968-981.	4.6	37
25	Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. <i>BMC Cancer</i> , 2010, 10, 656.	2.6	34
26	$^{18}\text{F}$ -FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 818-830.	6.4	34
27	Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 179-189.	2.5	34
28	Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. <i>Breast</i> , 2016, 29, 90-95.	2.2	31
29	CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 69649-69665.	1.8	29
30	Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. <i>Clinical Breast Cancer</i> , 2017, 17, 219-231.	2.4	28
31	Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancer. <i>Radiation Oncology</i> , 2018, 13, 49.	2.7	28
32	Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 192-196.	2.1	25
33	FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. <i>Oncology Reports</i> , 2005, 14, 415.	2.6	25
34	Secondary electrospray ionization-mass spectrometry and a novel statistical bioinformatic approach identifies a cancer-related profile in exhaled breath of breast cancer patients: a pilot study. <i>Journal of Breath Research</i> , 2015, 9, 031001.	3.0	25
35	Fluctuation of HER2 Expression in Breast Carcinomas during the Menstrual Cycle. <i>American Journal of Pathology</i> , 1999, 155, 1543-1547.	3.8	24
36	Omission of radiotherapy in elderly patients with early breast cancer: 15-Year results of a prospective non-randomised trial. <i>European Journal of Cancer</i> , 2015, 51, 1358-1364.	2.8	21

#	ARTICLE	IF	CITATIONS
37	Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers. <i>Acta Oncologica</i> , 2016, 55, 712-719.	1.8	20
38	Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2012-2020.	1.0	20
39	Classic Kaposi's Sarcoma: A Review of 90 Cases. <i>Journal of Dermatology</i> , 1992, 19, 548-552.	1.2	19
40	Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors. <i>Cells</i> , 2019, 8, 181.	4.1	19
41	Out-of-pocket costs for cancer survivors between 5 and 10 years from diagnosis: an Italian population-based study. <i>Supportive Care in Cancer</i> , 2016, 24, 2225-2233.	2.2	17
42	Proliferation of breast carcinoma during menstrual phases. <i>Lancet, The</i> , 1998, 352, 148-149.	13.7	16
43	Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. <i>BMC Cancer</i> , 2012, 12, 599.	2.6	16
44	Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 651.	2.6	16
45	The PDGFR <sup>2</sup> /ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 586.	2.6	16
46	Ex Vivo MRI Evaluation of Breast Tumors: A Novel Tool for Verifying Resection of Nonpalpable Only MRI Detected Lesions. <i>Breast Journal</i> , 2013, 19, 659-663.	1.0	12
47	Juvenile Classic Kaposi'S Sarcoma: A Report Of Two Cases, One With Family History. <i>Pediatric Hematology and Oncology</i> , 1994, 11, 409-416.	0.8	10
48	Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. <i>Annals of Oncology</i> , 2000, 11, 1137-1140.	1.2	10
49	Letter to the editor. <i>Breast Cancer Research and Treatment</i> , 2001, 70, 155-156.	2.5	10
50	A Breast Cancer Clinical Registry in An Italian Comprehensive Cancer Center: An Instrument for Descriptive, Clinical, and Experimental Research. <i>Tumori</i> , 2015, 101, 440-446.	1.1	10
51	Characterization of the Specificity by Immunohistology of a Monoclonal Antibody to a Novel Epithelial Antigen of Ovarian Carcinomas. <i>Pathology Research and Practice</i> , 1985, 180, 169-180.	2.3	9
52	Histopathological Characterization of a Novel Monoclonal Antibody, MLC1, Reacting with Lung Carcinomas. <i>Tumori</i> , 1988, 74, 401-410.	1.1	9
53	Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer. <i>Breast Care</i> , 2017, 12, 391-394.	1.4	9
54	Quadrantectomy is not a disfiguring operation for small breast cancer. <i>Breast</i> , 1994, 3, 3-7.	2.2	8

#	ARTICLE	IF	CITATIONS
55	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. <i>European Journal of Cancer</i> , 2006, 42, 1057-1061.	2.8	8
56	Circulating Sex Hormones and Tumor Characteristics in Postmenopausal Breast Cancer Patients. A Cross-Sectional Study. <i>International Journal of Biological Markers</i> , 2011, 26, 241-246.	1.8	8
57	Absence of interference of serum IgGs from patients with breast cancer and thyroid autoimmunity on the function of human iodide symporter gene stably transfected in CHO cells. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 862-865.	3.3	7
58	Significance of ipsilateral breast tumor recurrence after breast conserving treatment: role of surgical removal. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2013, 25, 22-31.	2.2	6
59	Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast. <i>Breast</i> , 2017, 35, 63-68.	2.2	5
60	HER2 and proliferation of wound-induced breast carcinoma. <i>Lancet, The</i> , 2003, 362, 1503.	13.7	4
61	HER2 and proliferation of wound-induced breast carcinoma. <i>Lancet, The</i> , 2003, 362, 1503.	13.7	4
62	Monoclonal Antibodies MBr1 and MBr8 as Predictors of Response to Oophorectomy in Advanced Breast Cancer. <i>Tumori</i> , 1988, 74, 309-312.	1.1	3
63	Radiopharmaceuticals for Breast Cancer Imaging. <i>Tumori</i> , 1997, 83, 512-514.	1.1	3
64	Androgen Receptor CAG Repeat Length and Estrogen Receptor Status in Postmenopausal Breast Cancer Prognosis. <i>International Journal of Biological Markers</i> , 2015, 30, 418-424.	1.8	3
65	Dynamics of the hazard for distant metastases after ipsilateral breast tumor recurrence according to estrogen receptor status: An analysis of 2851 patients. <i>Breast</i> , 2018, 40, 131-135.	2.2	3
66	Radionuclide imaging of unexpected multifocal breast cancer: surgical implications. <i>Breast</i> , 1997, 6, 386-387.	2.2	2
67	Is there a Specific Magnetic Resonance Phenotype Characteristic of Hereditary Breast Cancer?. <i>Tumori</i> , 2010, 96, 363-384.	1.1	2
68	Is the risk of primary hyperparathyroidism increased in patients with untreated breast cancer?. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 321-5.	3.3	2
69	Conservative treatment of breast cancer: Milan experience. <i>Acta Chirurgica Austriaca</i> , 1995, 27, 238-242.	0.2	1
70	What is specific in hereditary breast cancer? High T2 signal intensity as a new semeiotic pattern?. <i>European Journal of Radiology</i> , 2012, 81, S165-S170.	2.6	1
71	Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: Results and clinical implications after eight-years follow-up. <i>Breast</i> , 2014, 23, 334-340.	2.2	1
72	Cell Proliferation of the Primary Tumor Predicts Ipsilateral Axillary Node Disease in Elderly Breast Cancer Patients. <i>International Journal of Biological Markers</i> , 2013, 28, 24-31.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Reply to what if axillary lymph node dissection became less fashionable?. Cancer, 2014, 120, 2535-2536.	4.1	0
74	The Role of FDG-PET for Axillary Lymph Node Staging in Primary Breast Cancer. , 2008, , 157-167.		0